Advanced search
Publication Cover
Risk Management and Healthcare Policy Volume 12, 2019 - Issue
Submit an article Journal homepage
301
Views
11
CrossRef citations to date
0
Altmetric
Original Research

The Association Between Prolonged Proton Pump Inhibitors Use and Bone Mineral Density

Mohammad Reza Fattahi1 Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
,
Ramin Niknam1 Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, IranCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2608-8018
ORCID Icon,
Mesbah Shams2 Endocrine and Metabolism Research Center, Shiraz University of Medical Sciences, Shiraz, IranORCID Iconhttps://orcid.org/0000-0002-3210-0159
ORCID Icon,
Amir Anushiravani3 Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
,
Seyed Alireza Taghavi1 Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, IranORCID Iconhttps://orcid.org/0000-0002-3794-4377
ORCID Icon,
Gholamhossein Ranjbar Omrani2 Endocrine and Metabolism Research Center, Shiraz University of Medical Sciences, Shiraz, IranORCID Iconhttps://orcid.org/0000-0003-2224-7250
ORCID Icon &
Laleh Mahmoudi4 Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, IranORCID Iconhttps://orcid.org/0000-0003-3866-8519
ORCID Icon show all
Pages 349-355 | Published online: 12 Dec 2019

References

  • Rotman SR, Bishop TF. Proton pump inhibitor use in the U.S. ambulatory setting, 2002–2009. PLoS One. 2013;8(2):e56060. doi:10.1371/journal.pone.005606023418510
  • Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728–738. doi:10.1038/ajg.2009.11519240698
  • Freedberg DE, Kim LS, Yang YX, Risks T. Benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology. 2017;152(4):706–715. doi:10.1053/j.gastro.2017.01.03128257716
  • Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008;28(8):951–959. doi:10.1592/phco.28.8.95118657011
  • Ozdil K, Kahraman R, Sahin A, et al. Bone density in proton pump inhibitors users: a prospective study. Rheumatol Int. 2013;33(9):2255–2260. doi:10.1007/s00296-013-2709-023455632
  • Targownik LE, Goertzen AL, Luo Y, Leslie WD. Long-term proton pump inhibitor use is not associated with changes in bone strength and structure. Am J Gastroenterol. 2017;112(1):95–101. doi:10.1038/ajg.2016.48127845341
  • Targownik LE, Leslie WD, Davison KS, et al. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol. 2012;107(9):1361–1369. doi:10.1038/ajg.2012.20022777336
  • Lai SW, Lin CL, Liao KF. Proton pump inhibitors therapy and the risk of major osteoporotic non hip fractures in older adults in Taiwan. Eur J Gastroenterol Hepatol. 2019;31(2):272–273. doi:10.1097/MEG.000000000000131230575640
  • Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology. 2019;157(3):682–691. doi:10.1053/j.gastro.2019.05.05631152740
  • Laine L. Proton pump inhibitors and bone fractures? Am J Gastroenterol. 2009;104 Suppl 2:S21–6. doi:10.1038/ajg.2009.4819262543
  • Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106(7):1209–18; quiz 19. doi:10.1038/ajg.2011.113
  • Khalili H, Huang ES, Jacobson BC, et al. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ. 2012;344:e372. doi:10.1136/bmj.e37222294756
  • Adachi Y, Shiota E, Matsumata T, et al. Bone mineral density in patients taking H2-receptor antagonist. Calcif Tissue Int. 1998;62(4):283–285. doi:10.1007/s0022399004319504949
  • Solomon DH, Diem SJ, Ruppert K, et al. Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study. J Bone Miner Res. 2015;30(2):232–239. doi:10.1002/jbmr.234425156141
  • Hansen KE, Nieves JW, Nudurupati S, Metz DC, Perez MC. Dexlansoprazole and esomeprazole do not affect bone homeostasis in healthy postmenopausal women. Gastroenterology. 2019;156(4):926–934. doi:10.1053/j.gastro.2018.11.02330445008
  • Kanis JA, McCloskey EV, Johansson H, et al. A reference standard for the description of osteoporosis. Bone. 2008;42(3):467. doi:10.1016/j.bone.2007.11.00118180210
  • Schousboe JT, Shepherd JA, Bilezikian JP, Baim S. Executive summary of the 2013 ISCD position development conference on bone densitometry. JCD. 2013;16(4):455–467. doi:10.1016/j.jocd.2013.08.004
  • Looker AC, Melton LJ 3rd, Borrud LG, Shepherd JA. Changes in femur neck bone density in US adults between 1988-1994 and 2005-2008: demographic patterns and possible determinants. Osteoporos Int. 2012;23(2):771–780. doi:10.1007/s00198-011-1623-021625885

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.